20 potential launches, 11 therapy areas and 15 new drug classes. Our recent webinar, Key Potential Drug Launches in 2027: Expert Webinar, covered all of it. Evaluate’s expert analysts, Piotr...
The previous pieces in this series looked at the coverage gap from the outside: what it costs companies to be uncovered, and what they can do about it. This piece...
The previous piece in this series laid out why analyst coverage in healthcare is hard to come by: fewer analysts, a more complex sector, and economic incentives that push research...
Cell, gene, and nucleic acid therapies have been through plenty of cycles of excitement and doubt, and this latest one is more selective. Advanced therapies pipeline growth has slowed from...
A sell-side analyst tells a small or mid-cap healthcare company they are interested. The science is compelling, the data look promising, and management is accessible. Then nothing happens. The initiation...
There are more than a thousand publicly traded healthcare companies on US exchanges alone. Globally, hundreds more are listed on the LSE, Euronext, and exchanges across Asia-Pacific. Together they represent...
